NCT07160998 (X Life) is a NA clinical trial of Digital Lifestyle Therapeutic in Diabetes, sponsored by Li Huating.

Who is sponsoring NCT07160998?

NCT07160998 is sponsored by Li Huating.

What drugs are being tested in NCT07160998?

Interventions in NCT07160998: Digital Lifestyle Therapeutic, Standard Care.

Is NCT07160998 still recruiting?

NCT07160998 is currently completed. Last updated 12 February 2026.

Last reviewed 2026-02-12 · How we verify

NCT07160998: X Life

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Active Health-Based Comprehensive Study on Diabetes Management

Completed NA Last updated 12 February 2026

What this trial tests

NA trial testing Digital Lifestyle Therapeutic in Diabetes in 124 participants. Completed in 6 December 2025.

Timeline

7 September 2025

Primary endpoint
28 November 2025

6 December 2025

Quick facts

Lead sponsor	Li Huating
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	124
Start date	7 September 2025
Primary completion	28 November 2025
Estimated completion	6 December 2025
Sites	1 location across China

Drugs / interventions tested

Digital Lifestyle Therapeutic
Standard Care — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Li Huating

Who can join

Adults 40 to 70, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, open-label, multicenter trial evaluates the efficacy and safety of the AI-based lifestyle guidance system (X-Life) compared to standard care in adults with type 2 diabetes. X-Life integrates glucose level, wearable devices, and AI-driven decision models to provide personalized lifestyle recommendations. The primary endpoint is the percentage of time in glucose target range (TIR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Li Huating trials

Trials by the same sponsor.

NCT07160985 — AI-Assisted Blood Glucose Management Study · NA · completed
NCT07160972 — AI-Based Lifestyle Guidance Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07160998 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Li Huating
Last refreshed: 12 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07160998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing